Q & As

Q&As with scientists on their research and its applications or special topics in the field.

Reversing the Alzheimer’s Catastrophe

September 19, 2018

Dana Grantee Huntington Potter has found a promising potential treatment for Alzheimer’s by looking at the disease mechanisms of rheumatoid arthritis.

Connecting the Dots to Find a Protein that Affects Tau

March 21, 2018

A variety of brain troubles can trigger tau to form tangles, leading to diseases like chronic traumatic encephalopathy (CTE) and Alzheimer’s. While working to develop much-needed animal models that mimic the tricky process, Dana Foundation grantee Stanley Prusiner, M.D., found another protein, sortilin, that appears to govern tau’s actions.

Imaging Immune Therapies in Brain Tumor Patients

February 5, 2018

Brain tumors are the most common type of cancer occurring in children aged 14 and younger—as well as the leading cause of cancer death in that age group. Pediatric neurosurgeon Samuel Cheshier is working on new technologies to improve immunotherapy treatments and track their effectiveness over time.

When a Defective Heart Damages the Brain

October 3, 2017

Congenital heart defects, the most common type of birth defect, can lead to significant, long-lasting cognitive deficits. Dana Foundation grantee Daniel Licht discusses his research on preventing such deficits, and how the timing of surgery may be a key factor in improved outcomes.

Who's in Charge?

June 15, 2017

Sameer Sheth's discovery of conflict-sensitive cells in the cortex helps shed light on the neural circuitry of cognitive control.

Almost Invisible to the Immune Response

March 28, 2017

More than 30,000 people in the US contract Lyme disease each year; the inflammatory disorder can lead to long-term complications with the skin, heart, joints, and brain. We talk to Dana grantee Mark Wooten about his research into how the causal bacterium, Borrelia burgdorferi, can become almost invisible to the mammalian immune system after infection, making the disease difficult to diagnose and treat.

Music as the Brain’s Universal Language

January 24, 2017

In his recent research, Dana Foundation grantee Charles Limb found that musicians used the language areas of their brains when performing instrumental improvisation. In our new Scientist Q&A, he ponders the question: Could music be the mind’s universal language?

Brain Stimulation + Imaging Pack Dual Punch to Treat, Unravel Depression Circuitry

July 28, 2016

Amit Etkin's lab is investigating the use of repetitive transcranial magnetic stimulation (rTMS) in combination with whole-brain EEG and functional MRI (fMRI) to treat depression and to help unravel its underlying brain circuitry.

Q&A with Karel Svoboda

April 13, 2016

In April's Cerebrum article, "Imaging the Neural Symphony," a scientist who has helped pioneer this new form of technology—two-photon microscopy—writes about the development, current capabilities, and enormous promise that will permit neuroscientists go where they have never gone before.

Q&A with Lary C. Walker

March 10, 2016

In March Cerebrum article, “The Malignant Protein Puzzle,” two scientists who have collaborated for 30 years to identify the pathogenesis of Alzheimer’s disease and comprehend the role of abnormal proteins in neurodegeneration write about the latest advances in an area that has the potential to make a difference in helping people with dementia, Parkinson’s, CTE, ALS, and other neurodegenerative disorders. We asked co-author Walker to elaborate on some of their points.

Q&A with Richard Jope

February 17, 2016

In “Lithium to the Rescue,” the February Cerebrum article, Richard S. Jope, Ph.D., and Charles B. Nemeroff, M.D., Ph.D., write about the neuroprotective powers of lithium, an element Mother Nature has put in some drinking water sources. We asked Jope to elaborate on some of the points he and Nemeroff make in the article.

Q&A with Michael Baumann

January 26, 2016

In “The Changing Face of Recreational Drug Use,” the title of January’s Cerebrum article, author Michael H. Baumann, Ph.D., a staff scientist and facility head at the National Institute on Drug Abuse, Intramural Research Program, describes the complexity of the NPS problem, what is known about the molecular mechanisms of action, and the pharmacological effects of NPS. We asked him to elaborate on the article.
Page: 1 of 4